Discover a powerful, new (and somewhat unpopular) way to deal with anxiety and depression - without meditation, yoga, gratitude lists, pharmaceuticals and $49 Moleskine journals.
Similar Posts
New Study Will Investigate Psilocybin Therapy for Gambling Addiction
Researchers at Imperial’s Centre for Psychedelic Research will investigate psilocybin-assisted therapy for gambling addiction, aiming to improve their understanding of brain function in gambling disorder.
Fungus Among Us: 5 Fascinating Facts About Mushrooms
Science just keeps discovering how cool and beneficial mushrooms are, with or without psilocybin.
Can Virtual Reality Simulate the Effects of a Psychedelic Trip?
Researchers are studying the effects of novel VR applications to see if they can produce effects similar to psychedelics, but do they work?
Combining DMT with SSRIs Bolsters DMT’s Efficacy in Treating Severe Depression
The psychedelic renaissance movement was ignited by the idea that…
Interview With Henri Sant-Cassia, The Conscious Fund
Global Trac Solutions, Inc. CEO, David Flores sits down to speak with Co-Founding Partner at The Conscious Fund, Henri Sant-Cassia.
MORE Companies to UPLIST On NASDAQ? Compass Pathways Trial Results & More (CMPS, FTRP, MYCO, CYBN) 🚀
Compass Pathways (CMPS:NASDAQ) published amazing COMP360 Psilocybin Study results that will serve as support for companies working with psilocybin and psilocybin derivatives. However, this isn’t the only news worth mentioning.
Field Trip Health (FTRP: CSE) and (FTRPF: OTC) recently uplisted on the TSX ( Toronto Stock Exchange) and has filed an application to uplist on the Nasdaq.
While this is great news for Field Trip, it is not the only company who has filed to uplist. Silo Pharma, (SILO: OTC), has also put in an application to list on NASDAQ.
MagicMed will also join the ranks, however it will be through an acquisition.
Moreover, Cybin (CYBN: NEO,) and (CLXPF: OTC), is working on a transportable, wearable, helmet that completes a brain scan, through a partnership with a company called Kernel.
There is also news on Mydecine ( MYCO: NEO) and ( MYCOF: OTC) and MindCure (CSE: MCUR) (OTCQB: MCURF), so stay tuned till the end!
Enjoy the episode!
Timestamps:
0:00 – Intro
0:51 – Compass Pathways COMP360 Study Results
3:37 – Cybin Ketamine Study
7:14- Field Trip Uplists on the TSX And Applies To List On The NASDAQ
11:10 – Silo Pharma Applies To Uplist on The NASDAQ
12:11 – MagicMed to List On NASDAQ Through Acquisition
15:16- Mydecine Expands Cultivation Capabilities for Psilocybin
17:32- MINDCURE Completes First Stage of Manufacturing Synthetic Ibogaine
Links:
Compass Pathways Study Results On The Safety And Cognitive Effects Of Taking a Dose Of Psilocybin COMP360:
https://www.globenewswire.com/news-release/2021/06/03/2241445/0/en/COMPASS-Pathways-and-Kings-College-London-publish-cognition-results-from-COMP360-psilocybin-study-in-healthy-volunteers.html
Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine’s Psychedelic Effects on Cerebral Cortex Hemodynamics
https://psilocybinalpha.com/news/cybin-announces-sponsorship-of-a-kernel-flow-feasibility-study-to-measure-ketamines-psychedelic-effects-on-cerebral-cortex-hemodynamics
Field Trip Health Uplists on the TSX:
https://www.globenewswire.com/news-release/2021/06/03/2241200/0/en/Field-Trip-Health-Ltd-to-Commence-Trading-on-the-Toronto-Stock-Exchange-on-June-7-2021.html
FTRP Applies To Uplist On NASDAQ:
https://stockhouse.com/news/the-market-herald-news/2021/06/08/field-trip-health-tsx-ftrp-applies-to-list-on-nasdaq-stock-market
MagicMed Will Be Acquired by Nasdaq-listed Enveric Biosciences
https://psilocybinalpha.com/news/magicmed-to-be-acquired-by-nasdaq-listed-company
Health Canada Has Approved an Expansion of Mydecine’s Cultivation Capabilities for Psilocybin Producing Mushrooms MYCO: NEO), (MYCOF: OTC) :
https://finance.yahoo.com/news/health-canada-approves-expansion-mydecine-113000924.html
MINDCURE, (CSE: MCUR) (OTCQB: MCURF), Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research:
https://www.prnewswire.com/news-releases/mindcure-successfully-completes-first-stage-of-manufacturing-synthetic-ibogaine-for-use-in-psychedelic-clinical-research-301304810.html
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
editing:@themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#CompassPathways #Mydecine #FieldTrip